Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook

- Worldwide Sales Growth of 13.8 Percent -

ABBOTT PARK, Ill., April 16, 2008 /PRNewswire-FirstCall/ -- Abbott today announced financial results for the first quarter ended March 31, 2008.

     *    Diluted earnings per share, excluding specified items, were

          $0.63, reflecting 14.5 percent growth, at the upper end of Abbott's

          previously announced guidance range of $0.61 to $0.63. Diluted

          earnings per share under Generally Accepted Accounting Principles

          (GAAP) were $0.60, up 33.3 percent.

     *    Worldwide sales in the first quarter increased 13.8 percent to

          $6.8 billion, including a favorable 5.5 percent effect of exchange

          rates.

     *    Worldwide pharmaceutical sales increased 14.3 percent driven by

          double-digit growth in HUMIRA(R), Niaspan(R) and Kaletra(R) and

          9.8 percent growth in TriCor(R). Abbott forecasts global HUMIRA

          sales of more than $4 billion in 2008.

     *    Worldwide medical products sales increased 13.7 percent, driven by

          14.3 percent growth in worldwide Diabetes Care sales, 22.0 percent

          growth in international diagnostics sales, and 34.7 percent growth

          in international Vascular sales.

     *    Worldwide nutritional products sales were led by 20.8 percent growth

          in international nutritionals, with continued strong performance in

          key emerging growth markets.

     *    In March, Abbott and Takeda announced an agreement to conclude the

          TAP joint venture, evenly splitting the assets. Abbott will receive

          full U.S. ownership of Lupron, a complementary product to Abbott's

          emerging oncology pipeline, as well as future cash payments over the

          next five years.

     *    In the quarter, Abbott received five key regulatory approvals:

          HUMIRA for psoriasis and for juvenile rheumatoid arthritis,

          Simcor(R) for cholesterol, and the FreeStyle Freedom Lite(TM) and

          FreeStyle Navigator(R) glucose monitoring systems.


"Abbott started 2008 with a strong first quarter, following double-digit sales and earnings growth last year," said Miles D. White, chairman and chief executive officer, Abbott. "In addition, we received five key new product approvals during the quarter. The continued productivity of our late-stage pipeline, combined with the underlying strength of our broad mix of businesses, gives us a high level of confidence in our future growth outlook."

    The following is a summary of first-quarter 2008 sales.





    Sales Summary -                                                 Impact of

     Quarter Ended 3/31/08                 1Q08       % Change     Exchange on

                                       ($ millions)   vs. 1Q07      % Change


    Total Sales                            $6,766        13.8            5.5


        Total U.S. Sales                   $3,043         3.7 (a)        ---


        Total International Sales          $3,723        23.6           10.9


    Worldwide Pharmaceutical Sales         $3,854        14.3 (a)        5.9


        U.S. Pharmaceuticals               $1,752         3.6 (a)        ---


        International Pharmaceuticals      $2,102        25.1           11.9


    Worldwide Nutritional Sales            $1,110        10.8            3.0


        U.S. Nutritionals                    $583         3.0            ---


        International Nutritionals           $527        20.8            6.9


    Worldwide Diagnostics Sales (b)          $832        17.1            8.1


        U.S. Diagnostics                     $211         4.6            ---


        International Diagnostics            $621        22.0           11.3


    Worldwide Vascular Sales                 $452         7.6            4.9


         U.S. Vascular                       $214       (12.0)           ---


         International Vascular              $238        34.7           11.7


    Other Sales (c)                          $518        17.3            4.7



    (a) Reflects the impact of generic competition for Omnicef in May 2007.

    (b) Includes sales from the molecular diagnostics and core laboratory

        diagnostics businesses, which includes point of care.

    (c) Includes sales from diabetes, bulk pharmaceuticals, spine and animal

        health businesses.


    Note:  See "Consolidated Statement of Earnings" for more information.




    The following is a summary of Abbott's first-quarter 2008 sales for

selected products.




    Quarter Ended 3/31/08

                                    Percent        Percent           Percent

    (dollars in millions)           Change   Rest  Change            Change

                              U.S.    vs.     of     vs.     Global    vs.

                             Sales   1Q07   World   1Q07     Sales    1Q07

    Pharmaceutical Products

    HUMIRA                    $402   38.8    $476   68.9 (a)  $878    53.7

    Depakote                  $341   11.7     $24   12.2      $365    11.7

    Kaletra                   $113   (3.2)   $240   31.2 (b)  $353    17.8

    TriCor                    $245    9.8     ---    ---      $245     9.8

    Biaxin (clarithromycin)     $6  (17.4)   $216   (0.4)(c)  $222    (1.0)

    Ultane/Sevorane            $44   (9.0)   $143   13.8 (d)  $187     7.4

    Niaspan                   $176   24.2     ---    ---      $176    24.2

    Synthroid                  $94  (16.5)    $21   28.1      $115   (10.7)


    Nutritional Products

    Pediatric Nutritionals    $305    4.5    $293   24.5      $598    13.5

    Adult Nutritionals        $271    3.9    $234   16.4 (e)  $505     9.3


    Medical Products

    Abbott Diabetes Care      $136    3.8    $189   23.2 (f)  $325    14.3

    Coronary Stents            $75  (11.8)   $114   52.5 (g)  $189    18.2

    Other Coronary             $78  (12.3)    $87   19.8 (h)  $165     2.0

    Endovascular               $61  (11.8)    $37   25.8 (i)   $98    (0.6)



    (a) Without the positive impact of exchange of 17.3 percent, HUMIRA sales

        increased 51.6 percent internationally.

    (b) Without the positive impact of exchange of 10.5 percent, Kaletra sales

        increased 20.7 percent internationally.

    (c) Without the positive impact of exchange of 9.6 percent, clarithromycin

        sales decreased 10.0 percent internationally.

    (d) Without the positive impact of exchange of 9.4 percent, Sevorane sales

        increased 4.4 percent internationally.

    (e) Without the positive impact of exchange of 8.9 percent, Adult

        Nutritionals sales increased 7.5 percent internationally.

    (f)  Without the positive impact of exchange of 12.3 percent, Abbott

        Diabetes Care sales increased 10.9 percent internationally.

    (g) Without the positive impact of exchange of 13.2 percent, Coronary

        Stents sales increased 39.3 percent internationally.

    (h) Without the positive impact of exchange of 9.7 percent, Other Coronary

        sales increased 10.1 percent internationally.

    (i) Without the positive impact of exchange of 12.4 percent, Endovascular

        sales increased 13.4 percent internationally.




    Business Highlights


     *    Simcor(R) Approved in United States -- Abbott received U.S. Food and

          Drug Administration (FDA) approval of its cholesterol therapy,

          Simcor, a fixed-dose combination of Niaspan(R) and simvastatin.

          Simcor combines these two well-established medications to target LDL

          (bad cholesterol), HDL (good cholesterol) and triglycerides in a

          single pill.


     *    HUMIRA(R) Indications Approved

          o    Psoriasis -- Abbott received FDA approval for HUMIRA to treat

               moderate to severe plaque psoriasis. In clinical trials, nearly

               75 percent of patients treated with HUMIRA achieved a

               75 percent reduction in psoriasis symptoms. Psoriasis affects

               125 million people worldwide.

          o    Juvenile Rheumatoid Arthritis (JRA) -- Also in the quarter,

               Abbott received FDA approval for HUMIRA to treat moderate to

               severely active polyarticular juvenile idiopathic arthritis,

               commonly referred to as JRA in the United States.

          o    RA in Japan -- In April, Abbott also received Japanese approval

               for HUMIRA to treat RA.


     *    TAP Joint Venture to Conclude -- In March, Abbott and Takeda

          Pharmaceutical announced an agreement to conclude their 31-year TAP

          joint venture. Abbott and Takeda will evenly split the value and

          assets of the joint venture, with Abbott receiving full ownership of

          the oncology treatment, Lupron, including its U.S. commercial

          organization, as well as future cash payments from Takeda over the

          next five years. The transaction is expected to close in the second

          quarter of 2008.


     *    Data Presented at the American College of Cardiology (ACC)

          Conference

          o    TriLipix(R) -- Abbott presented Phase III data on TriLipix,

               formerly known as ABT-335, Abbott's next-generation fenofibrate

               therapy. Data demonstrated that TriLipix, in combination with

               statin therapy, is safe and effective at improving three key

               lipids, HDL, LDL and triglycerides.

          o    Xience(TM) V -- Abbott also presented data on its Xience V

               drug-eluting stent. Results from the SPIRIT II clinical trial

               outside the United States demonstrated that after two years,

               patients with the Xience V stent experienced a 40 percent

               reduction in major adverse cardiac events (MACE) compared to

               Boston Scientific's Taxus drug-eluting stent. Two-year results

               from Abbott's U.S. pivotal trial, SPIRIT III, have been

               accepted as a LateBreaker presentation at the upcoming EuroPCR

               meeting in mid-May.


     *    FreeStyle Navigator(R) and FreeStyle Freedom Lite(TM) Available in

          United States -- In March, Abbott received FDA approval of the

          FreeStyle Navigator Continuous Glucose Monitoring System. Worn on

          the abdomen or arm, FreeStyle Navigator monitors glucose levels and

          provides minute-by-minute trend information. The FreeStyle Freedom

          Lite blood glucose monitor is also now available, improving patient

          convenience by eliminating the manual calibration required by most

          meters.


     *    ARCHITECT(R) i1000SR(R) Approved -- Abbott introduced the ARCHITECT

          i1000SR immunochemistry analyzer in the United States, expanding its

          ARCHITECT family of diagnostic instrument systems. Designed to help

          improve productivity in small-volume labs, the instrument addresses

          common laboratory workflow challenges through innovative sample

          processing and reagent management.


     *    Abbott Molecular Development Agreement -- Abbott entered into an

          agreement with Genentech, Hoffmann-La Roche and OSI Pharmaceuticals

          to develop a gene-based test to assess the clinical benefit of

          Tarceva (erlotinib). Under the agreement, Abbott will develop a test

          to detect extra copies of the epidermal growth factor receptor

          (EGFR) gene in non-small cell lung cancer patients.


Abbott confirms earnings-per-share guidance for the full-year 2008 and issues earnings-per-share guidance for the second-quarter 2008

Abbott is confirming earnings-per-share guidance for the full-year 2008 of $3.20 to $3.25, and is providing earnings-per-share guidance of $0.78 to $0.80 for the second quarter, both excluding specified items. As previously announced, Abbott expects the TAP transaction to close in the second quarter and to be neutral to earnings per share in 2008 and neutral or better over the next five years.

Abbott forecasts specified items for the full-year 2008 of approximately $0.08 per share, including previously announced cost reduction initiatives. Including specified items, projected earnings per share under GAAP would be $3.12 to $3.17.

Abbott forecasts specified items for the second-quarter 2008 of approximately $0.03 per share, primarily associated with previously announced cost reduction initiatives. Including these specified items, projected earnings per share under GAAP would be $0.75 to $0.77.

Abbott increases quarterly dividend

On Feb. 15, 2008, the board of directors increased the company's quarterly common dividend to 36 cents per share, an increase of 10.8 percent. The cash dividend is payable May 15, 2008, to shareholders of record at the close of business on April 15, 2008. This marks the 36th consecutive year that Abbott has increased its dividend payout and the 337th consecutive dividend paid by Abbott.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com. Abbott will webcast its live first-quarter earnings conference call through its Investor Relations Web site at http://www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.


             - Private Securities Litigation Reform Act of 1995 -

               A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. We caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2007, and are incorporated by reference. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


                     Abbott Laboratories and Subsidiaries

                      Consolidated Statement of Earnings

                 First Quarter Ended March 31, 2008 and 2007

                                 (unaudited)


                                                                     Percent

                                          2008            2007       Change


    Net Sales                        $6,765,603,000  $5,945,561,000   13.8

    Cost of products sold             2,961,072,000   2,592,011,000   14.2

    Research and development            619,957,000     619,056,000    0.1

    Acquired in-process research &

     development                         18,700,000             ---   n/m

    Selling, general and

     administrative                   2,018,033,000   1,786,869,000   12.9

    Total Operating Cost and

     Expenses                         5,617,762,000   4,997,936,000   12.4


    Operating earnings                1,147,841,000     947,625,000   21.1


    Net interest expense                 93,178,000     124,205,000  (25.0)

    Net foreign exchange (gain) loss      6,221,000       4,851,000   28.2

    (Income) from TAP Pharmaceutical

     Products Inc. joint venture       (101,942,000)   (146,632,000) (30.5)

    Other (income) expense, net         (10,342,000)    124,536,000   n/m   1)

    Earnings before taxes             1,160,726,000     840,665,000   38.1

    Taxes on earnings                   222,859,000     143,128,000   55.7


    Net Earnings                       $937,867,000    $697,537,000   34.5


    Net Earnings Excluding Specified

     Items, as described below         $987,724,000    $854,107,000   15.6  2)


    Diluted Earnings Per Common

     Share                                    $0.60           $0.45   33.3


    Diluted Earnings Per Common

     Share, Excluding Specified

     Items, as described below                $0.63           $0.55   14.5  2)


    Average Number of Common Shares

     Outstanding Plus Dilutive Common

     Stock Options and Awards         1,560,567,000   1,558,234,000



    1) Other (income) expense, net in 2008 and 2007 is primarily related to

       Abbott's ownership of Boston Scientific stock. These items have been

       reflected as specified items as discussed in Q&A Answer 5.


    2) 2008 Net Earnings Excluding Specified Items excludes after-tax charges

       of $37 million, or $0.02 per share, for cost reduction initiatives and

       other, $15 million, or $0.01 per share, for acquired in-process

       research & development related to a molecular diagnostic technology

       investment and $7 million, or $0.01 per share, for acquisition

       integration; partially offset by an after-tax gain of $9 million, or

       $0.01 per share, on sales of Boston Scientific stock.


       2007 Net Earnings Excluding Specified Items excludes after-tax charges

       of $57 million, or $0.04 per share, for acquisition integration,

       $75 million, or $0.05 per share, related to fair value adjustments of

       Abbott's investment in Boston Scientific stock and related gain-sharing

       aspect, and $55 million, or $0.03 per share, for cost reduction

       initiatives and other, partially offset by $31 million, or $0.02 per

       share, for suspended depreciation and amortization related to the

       proposed sale of the diagnostics business.


    NOTE: See attached questions and answers section for further explanation

          of Consolidated Statement of Earnings line items.


    n/m = Percent change is not meaningful.




                             Questions & Answers


     Q1)  What drove the 14.3 percent worldwide pharmaceutical sales growth?


     A1)  International pharmaceutical sales increased 25.1 percent during the

          quarter, including an 11.9 percent favorable impact from exchange.

          International growth was driven by HUMIRA,  which grew nearly

          70 percent, and Kaletra, which grew 31.2 percent, based on the

          continued strength of the international launch of Kaletra tablets.


          U.S. pharmaceutical sales growth of 3.6 percent was impacted by the

          expected decline in Omnicef sales, as generic competition for the

          product began in May 2007. Excluding the impact from Omnicef, U.S.

          pharmaceutical sales increased approximately 14 percent. Growth in

          the quarter was driven by HUMIRA, which increased nearly 40 percent

          as market demand continued to grow across the rheumatology,

          dermatology and gastroenterology segments. The launch of the

          psoriasis indication is proceeding well, with strong HUMIRA market

          share gains in the first two months since launch. Abbott forecasts

          global HUMIRA sales of more than $4 billion in 2008. Niaspan and

          TriCor also performed well, increasing 24.2 percent and 9.8 percent,

          respectively. Total lipid franchise sales growth, including TriCor,

          Niaspan and Simcor, exceeded 20 percent.



     Q2)  What drove the double-digit growth in global nutritionals and

          medical products sales?


     A2)  Global Nutritional sales performance was led by 20.8 percent growth

          in international nutritionals, including a 6.9 percent favorable

          impact from exchange, with continued strong growth in Latin American

          and Asian markets.


          Medical products sales growth of 13.7 percent was led by global

          diagnostics sales, which increased 17.1 percent, including an

          8.1 percent favorable impact from exchange. Point of care sales grew

          21.7 percent and Abbott Molecular also increased more than

          21 percent. Worldwide Diabetes Care sales grew 14.3 percent. Abbott

          Vascular achieved sales of more than $450 million, led

          by 34.7 percent international growth. Results include continued

          growth in Coronary Stents, including Xience V internationally. Other

          Coronary sales reflect lower third-party catheter sales due to an

          expected year-over-year decline in the percutaneous coronary

          intervention (PCI) market. However, U.S. PCI volumes were up

          sequentially versus the fourth quarter of 2007, and U.S.

          drug-eluting stent (DES) penetration improved to the mid-to-high

          60 percent range in March. In addition, in the first quarter, Abbott

          launched Xience V in France, Europe's second- largest DES market,

          and the launch is off to a strong start.



     Q3)  What drove SG&A and R&D spending in the quarter?


     A3)  The company is on track for a significant number of major new

          product launches in 2008. In the quarter, Abbott received approval

          for five new products or indications, including HUMIRA to treat

          psoriasis and juvenile rheumatoid arthritis, Simcor to treat

          cholesterol, and the FreeStyle Freedom Lite and the FreeStyle

          Navigator glucose monitoring systems.


          SG&A expense included new and ongoing promotional initiatives,

          including spending to support the launch of two new indications for

          HUMIRA, the launch of Simcor and the upcoming U.S. launch of Xience

          V, which the company expects in the second quarter of 2008.


          R&D expense in the quarter was 9.2 percent of sales, in line with

          previous guidance. The comparison to the prior year is impacted by

          the timing of R&D spending, with higher levels of R&D expense in the

          prior year supporting significant late-stage pipeline activity.

          Growth in R&D spending for the full year is expected to be in the

          mid-to-high single digits.



     Q4)  How does the first-quarter gross margin profile compare to the prior

          year?


     A4)  The gross margin ratio before and after specified items is shown

          below (dollars in millions):




                                         1Q08                   1Q07

                                Cost of          Gross Cost of          Gross

                                Products Gross  Margin Products Gross  Margin

                                  Sold   Margin    %     Sold   Margin    %


    As reported                  $2,961  $3,805  56.2%  $2,592  $3,354  56.4%

    Adjusted for specified items:

     Cost reduction initiatives

      and other                    ($31)    $31   0.5%    ($56)    $56   0.9%

     Acquisition integration        ($4)     $4   0.1%    ($23)    $23   0.4%

     Suspended depreciation and

      amortization                    -       -      -     $32    ($32) (0.5%)

    As adjusted                  $2,926  $3,840  56.8%  $2,545  $3,401  57.2%




          The first-quarter 2008 adjusted gross margin ratio was 56.8 percent.

          The comparison to 2007 was negatively impacted by generic

          competition for Omnicef and the impact of foreign exchange on the

          ratio. The gross margin ratio for the full year is expected to be

          approximately 58 percent.



     Q5)  How did specified items affect reported results?


     A5)  Specified items impacted first-quarter results as follows (dollars

          in millions, except earnings-per-share data):




                                           1Q08                  1Q07

                                     Earnings              Earnings

                                           After-                After-

                                  Pre-tax   tax    EPS   Pre-tax  tax    EPS


    As reported                    $1,161  $938   $0.60    $841  $698   $0.45

    Adjusted for specified items:

     Cost reduction initiatives

      and other                       $44   $37   $0.02     $70   $55   $0.03

     Acquired in-process R&D          $19   $15   $0.01       -     -       -

     Acquisition integration           $9    $7   $0.01     $71   $57   $0.04

     (Gain) on sale of BSX stock

      and fair-value adjustments

      for BSX stock and financial

      instruments                    ($11)  ($9) ($0.01)   $124   $75   $0.05

     Suspended depreciation and

      amortization                      -     -       -    ($39) ($31) ($0.02)

    As adjusted                    $1,222  $988   $0.63  $1,067  $854   $0.55




          Cost reduction initiatives and other relate primarily to remaining

          costs associated with previously announced efforts to improve

          efficiencies in our global manufacturing operations. This includes

          actions announced last year to streamline operations in our vascular

          business. Acquired in-process research and development

          relates to a molecular diagnostic technology investment that took

          place in the quarter. Acquisition integration primarily relates to

          remaining costs associated with acquisitions. Regarding Boston

          Scientific (BSX) stock, the amount in the first quarter of 2008

          relates to realized gains on the disposition of BSX stock and in the

          prior year relates primarily to changes in fair value. Amounts this

          quarter represent final gains on sale as all shares of BSX stock

          have now been sold.


          The pre-tax impact of the specified items by Consolidated Statement

          of Earnings line item is as follows (dollars in millions):




                                                        1Q08

                                         Cost of                      Other

                                         Products                   (Income)/

                                           Sold    R&D  IPR&D  SG&A  Expense


    As reported                           $2,961  $620   $19  $2,018  ($10)

    Adjusted for specified items:

     Cost reduction initiatives and other    $31     -     -     $13     -

     Acquired in-process R&D                   -     -   $19       -     -

     Acquisition integration                  $4    $1     -      $4     -

     (Gains) on sales of BSX stock             -     -     -       -  ($11)

    As adjusted                           $2,926  $619     -  $2,001    $1




     Q6)  What was the tax rate in the quarter?


     A6)  In line with the previous forecast, the tax rate this quarter was

          19.2 percent.



     Q7)  How did the TAP joint venture perform this quarter?


     A7)  Income from the TAP joint venture was in line with previous

          forecasts. Prevacid sales were $550 million and Lupron sales were

          $147 million.


          In March, Abbott and Takeda announced an agreement to conclude the

          TAP joint venture, evenly splitting the assets. Abbott expects the

          transaction to be neutral to 2008 earnings per share and neutral or

          better over the next five years. The transaction is expected to

          close in the second quarter of 2008.


          After the close of the transaction, Abbott will no longer record TAP

          joint venture income. Instead, U.S. Lupron sales and costs

          associated with the franchise will be included in Abbott's operating

          results. Abbott will also record, as other income, the estimated

          future cash payments from Takeda of approximately $1.5 billion over

          the next five years based on TAP's current and future product

          portfolio.



     Q8)  What are some near-term opportunities from Abbott's pipeline?


     A8)  Abbott has a number of promising late-stage programs in its

          pharmaceutical and medical products pipeline, including:


          *    HUMIRA

               o    Psoriasis -- Launched in Europe and the United States in

                    the first quarter of 2008.

               o    Juvenile RA -- Received regulatory approval in the first

                    quarter of 2008.

               o    Ulcerative colitis -- Currently in Phase III development.

               o    RA in Japan -- Received approval in April 2008.


          *    XIENCE V Drug-Eluting Stent (DES) -- Launched outside the

               United States, submitted to the U.S. Food and Drug

               Administration (FDA) and is currently under regulatory review.

               In the fourth-quarter 2007, an FDA advisory panel recommended

               approval of Xience V. Abbott expects a U.S. launch in the

               second-quarter 2008. Two-year results from the U.S. pivotal

               trial, SPIRIT III, have been accepted as a LateBreaker

               presentation at the EuroPCR meeting in mid-May.


          *    Controlled-release Vicodin -- A controlled-release form of

               Abbott's pain brand, Vicodin, was submitted for U.S. regulatory

               approval in the fourth quarter of 2007. Results from the

               pivotal Phase III clinical trial will be presented at the

               American Pain Society meeting in May.


          *    Simcor -- Simcor, a combination therapy to address both HDL and

               LDL cholesterol, was approved in the United States in the first

               quarter of 2008.


          *    TriLipix (ABT-335) -- TriLipix, a next-generation fenofibrate,

               was submitted for U.S. regulatory approval in the fourth

               quarter of 2007. Phase III data were presented at the American

               College of Cardiology meeting in March. In addition, TriLipix

               is part of the fixed-dose combination with Crestor that is in

               Phase III development.


          *    ABT-874 -- In Immunology, Abbott's anti-IL-12/23 biologic,

               ABT-874, has demonstrated promising results in early studies

               for Crohn's disease and psoriasis. Abbott moved ABT-874 into

               Phase III development for psoriasis in December 2007.


          *    Flutiform -- A combination asthma treatment in Phase III

               development, Flutiform is expected to launch in 2009.


          *    Diabetes Care Pipeline -- FreeStyle Freedom Lite was launched

               internationally last year and was recently launched in the

               United States. Abbott's FreeStyle Navigator Continuous Glucose

               Monitoring System was launched in Europe last year and was

               approved in the United States in the first quarter of 2008.

               Also in development is a fully integrated blood glucose

               monitoring system combining a meter, test strips and lancing

               capabilities in one device.


          *    m2000 Molecular Diagnostics System -- Last year, Abbott

               received FDA approval for the RealTime HIV-1 viral load test

               for use on the m2000 molecular diagnostics system. Abbott

               expects to expand its U.S. menu of infectious disease assays

               over the next few years.


          *    Core Laboratory Diagnostics -- In April, Abbott introduced the

               ARCHITECT i1000SR immunochemistry analyzer in the United

               States, expanding its ARCHITECT family of diagnostic instrument

               systems for clinical laboratories.



     Q9)  What are some mid- and early-stage opportunities in Abbott's

          broad-based pipeline?


     A9)  Abbott is advancing leading-edge scientific discoveries in its

          mid- and early-stage pharmaceutical and medical products pipeline.

          Following are selected areas of emphasis:


          *    Neuroscience

               o    Abbott's neuroscience pipeline includes several unique

                    approaches for treating a number of diseases including

                    schizophrenia, ADHD, Alzheimer's disease and pain.

                    Compounds under development target neuronal nicotinic

                    receptors (NNRs), which play a role in regulating pain,

                    memory and other neurological functions.


          *    Oncology

               o    In 2007, Abbott announced a collaboration with Genentech

                    to develop and commercialize two Abbott-discovered

                    oncology compounds. These include a multi-targeted kinase

                    inhibitor and Bcl-2 family protein antagonist. Both

                    represent promising, unique approaches to treating cancer.

                    Abbott and Genentech will work together on all aspects of

                    research, development and commercialization.


               o    Additional oncology compounds in Abbott's pipeline that

                    are not part of the collaboration include: a

                    PARP-inhibitor, which prevents DNA repair in cancer cells,

                    enhancing the effectiveness of current cancer therapies;

                    an oral anti-mitotic in Phase II for non-small cell lung

                    cancer and neuroblastoma; and, a biologic anti-tumor agent

                    with a novel mechanism of action.


          *    Hepatitis C

               o    Abbott has partnered with Enanta Pharmaceuticals to

                    develop protease inhibitors for the treatment of hepatitis

                    C (HCV), which affects more than 170 million people

                    worldwide. Abbott also has an internal HCV polymerase

                    program in early-stage development.


          *    Bioabsorbable Drug-Eluting Stent

               o    Abbott has presented promising data from the world's first

                    clinical trial (ABSORB) for a fully-bioabsorbable

                    drug-eluting stent (DES) to treat coronary artery disease.

                    The bioabsorbable DES is designed to be slowly and

                    completely metabolized by the body over time.

CONTACT: Financial, John Thomas, +1-847-938-2655, Larry Peepo,+1-847-935-6722, or Tina Ventura, +1-847-935-9390, or Media, Melissa Brotz,+1-847-935-3456, Scott Stoffel, +1-847-936-9502, all of Abbott

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: April 2008


View comments

Hide
(web4)